Ariana Pelosci

Findings from the phase 2 TRANSCEND-PILOT-017006 supported the use of lisocabtagene maraleucel as a second-line treatment for patients with large B-cell lymphoma who were not able to or didn’t want to receive hematopoietic stem cell transplant.

Serial postoperative ctDNA analysis could be a useful tool in guiding treatment decisions and improving care for patients with stage III colorectal cancer.

Radical proctectomy, external beam radiotherapy, and brachytherapy yielded comparable prostate cancer–specific mortality, while external beam radiotherapy with or without brachytherapy resulted in favorable distant metastases outcomes in patients with high-risk prostate cancer.

Results from cohort K of the phase 1b/2 KEYNOTE-869 trial showed improved responses for patients with advanced or metastatic urothelial carcinoma when treated with enfortumab vedotin-efjv plus pembrolizumab.

A health-related quality of life survey found similar outcomes between those treated with pembrolizumab plus axitinib vs sunitinib in advanced renal cell carcinoma.

Findings from the phase 1/2 FAKTION trial indicated that survival had increased following the addition of capivasertib to fulvestrant for patients with aromatase inhibitor–resistant, estrogen receptor–positive, HER2-negative advanced breast cancer.

Trastuzumab deruxtecan was granted priority review by the FDA for patients with unresectable advanced or metastatic HER2-low breast cancer.

The primary end points of progression-free survival and overall survival were not met in the phase 3 OVAL trial assessing ofranergene obadenovec for patients with platinum-resistant ovarian cancer.

Patients with solid tumors undergoing treatments with chemotherapy, immunotherapy, or chemoimmunotherapy mounted an adequate antibody response to the mRNA-1273 COVID-19 vaccine.

Results from a phase 1/2 trial highlighted improved clinical outcomes for patients receiving eltanexor monotherapy for relapsed/refractory myelodysplastic syndrome.

Dexamethasone, Cisplatin, gemcitabine, and pegaspargase resulted in improved preliminary outcomes vs dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide for patients with newly diagnosed locally advanced stage III or IV extranodal natural killer/ T-cell lymphoma.

Investigators reported a reduction in racial and ethnic disparities among patients with de novo stage IV breast cancer following implementation of Medicaid expansion, and included a decreased risk of death for patients in a racial/ethnic minority compared with White patients.

Patients with pancreatic and extrapancreatic neuroendocrine tumors treated with atezolizumab plus bevacizumab experienced consistent clinical responses and a progression-free survival consistent with other therapies.

CV-01 delivery of sonodynamic therapy has been granted orphan drug designation and fast track designation by the FDA for the treatment of recurrent glioblastoma.

The FDA has delayed the decision to approve tislelizumab monotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma following prior systemic therapy, due to COVID-19 travel restrictions.

At 24 months of follow-up, MRI-guided focused ultrasound focal therapy was found to be safe and effective for patients with grade group 2 or 3 prostate cancer.

The FDA has accepted a biologics license application for vic-trastuzumab duocarmazine for patients with HER2-positive unresectable locally advanced or metastatic breast cancer.

The primary end point of progression-free survival was met in the phase 3 COSMIC-313 trial which investigated cabozantinib, nivolumab, and ipilimumab in previously untreated, advanced intermediate- or poor-risk renal cell carcinoma.

Results from the phase 2 APPROVE trial showed apatinib plus pegylated liposomal doxorubicin improved efficacy and safety compared with pegylated liposomal doxorubicin alone for patients with platinum-resistant recurrent ovarian cancer.

Patients with low-risk locoregionally advanced nasopharyngeal carcinoma who received 2 cycles of concurrent cisplatin plus intensity-modulated radiotherapy compared with 3 cycles had better survival and manageable toxicities.

Those with non–small cell lung cancer who had increasing tumor mutational burden appeared to experience better inflammatory T-cell–mediated responses compared with those who had low tumor mutational burden.

The phase 2 CTMX-2009-002 trial met its primary end point of confirmed objective response greater than 10% for patients with hormone receptor–positive, HER2–non-amplified breast cancer being treated with praluzatamab ravtansine.

Black adolescent young adult patients with acute myeloid leukemia appeared to have inferior outcomes compared with White patients.

The phase 3 RATIONALE 306 trial showed improved overall survival for patients receiving tislelizumab plus chemotherapy vs placebo and chemotherapy for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 status.

Results from the phase 3 AEGEAN trial showed an improved pathological complete response in patients with resectable non–small cell lung cancer treated with durvalumab plus neoadjuvant chemotherapy vs chemotherapy alone.

Steven J. Chmura, MD, PhD, discussed recent findings from the phase 2R/3 NRG-BR002 trial in patients with newly diagnosed oligometastatic breast cancer.

Metastatic castration-resistant prostate cancer tumors can be classified as luminal and basal, possibly allowing for a better precision medicine approach to treatment.

Patients with p53-mutated non–small cell lung cancer who were given ALRN-6924 completed more cycles of treatment with chemotherapy vs the placebo arm.

Fast track designation was granted to PDS0101 plus pembrolizumab, which is currently being assessed in the phase 2 VERSATILE study in patients with recurrent or metastatic human papillomavirus 16–positive head and neck cancer.

The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended for approval trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive breast cancer.